No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TVTX Travere Therapeutic
- 9.800
- -0.010-0.10%
Close Jul 19 16:00 ET
746.06MMarket Cap-4924P/E (TTM)
9.960High9.565Low580.56KVolume9.840Open9.810Pre Close5.65MTurnover1.04%Turnover RatioLossP/E (Static)76.13MShares17.57052wk High10.07P/B549.82MFloat Cap5.12052wk Low--Dividend TTM56.10MShs Float37.040Historical High--Div YieldTTM4.03%Amplitude0.000Historical Low9.735Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Travere Therapeutics, Inc. (NASDAQ:TVTX) Held Back By Insufficient Growth Even After Shares Climb 31%
Travere Therapeutics, Inc. (NASDAQ:TVTX) shares have continued their recent momentum with a 31% gain in the last month alone. Unfortunately, the gains of the last month did little to right the
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Nvidia, Micron Leading Chip Stocks Higher Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.Shares of NVIDIA Corporation (NASDAQ:NVDA) rose during Tuesday's session.Keybanc analyst John Vinh maintained
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July
Shareholders in Travere Therapeutics (NASDAQ:TVTX) Are in the Red If They Invested Five Years Ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to
Comments
$Travere Therapeutic(TVTX.US$
NEWS
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics to present data on FILSPARI at prestigious medical conferences, demonstrating the potential superiority of FILSPARI over existing treatments
Analyses show FILSPARI's ability to slow kidney function decline in patients with IgA nephropathy, offering a new approach to patient care
New 48-week findings from...
NEWS
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics to present data on FILSPARI at prestigious medical conferences, demonstrating the potential superiority of FILSPARI over existing treatments
Analyses show FILSPARI's ability to slow kidney function decline in patients with IgA nephropathy, offering a new approach to patient care
New 48-week findings from...
1
$Travere Therapeutic(TVTX.US$ Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...
1
8
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
The continuous decline in share price and revenue indicates unresolved challenges within the company. The company's future growth is uncertain and there are 4 warning signs in the investment analysis of Travere Therapeutics.
1
$Travere Therapeutic(TVTX.US$ Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg